Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kodak Establishes Pharmaceutical Unit To Tackle Shortages

US Development Bank Signs $765m Loan For Kodak

Executive Summary

Kodak’s new pharmaceutical unit receives a $765m loan from the US International Development Finance Corporation, through President Trump’s Defense Production Act, to produce critical pharma components that are essential but have lapsed into chronic national shortage, as defined by the FDA.

You may also be interested in...



‘Patience Young Grasshopper’: Former Phlow Exec Admits Securities Fraud Over US Kodak Loan

Kodak’s surprise announcement in July 2020 that it was looking to secure a massive government loan to set up a pharma division at the height of the COVID-19 pandemic was leaked by an executive at Phlow, which was assisting the firm, to his cousin, allowing both men to realize hundreds of thousands of dollars in illicit profits from fraudulent share trading.

Pandemic Perspectives: Cracks In Global Supply Chain Lead To Localization Trend

Weaknesses in the global pharmaceutical supply chain, exposed and exacerbated by the coronavirus pandemic, have led major markets to pursue localization policies aimed at bolstering domestic production capacity. But any significant transformation promises to take many years.

AAM Welcomes Biden Moves To Strengthen Supply Chain

US president Joe Biden’s latest executive order directing a review of the API supply chain has been welcomed by the country’s off-patent industry.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB150119

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel